Latham & Watkins LLP has advised Cheplapharm Arzneimittel GmbH (Cheplapharm), a European leader in well-established medicines, on its €1.2 billion seven-year term loan B. The proceeds will be used to partially refinance Cheplapharm’s existing €1.28 billion term loan B due 2029.
The refinancing follows Cheplapharm’s recently announced strategic partnership with Sanofi. Earlier this year, Cheplapharm also issued €950 million 6.75% senior secured notes due 2032. Latham & Watkins advised Cheplapharm on both of these transactions.
The Latham team was led by Frankfurt Capital Markets partner Jan Penselin, Frankfurt Banking & Private Credit partner Alexandra Hagelüken, and counsel Cora Grannemann, with associate Yan Ma. Advice was also provided on capital markets matters by associates Peter Neuböck and Tobias Müller.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
